App-Quantinova.ai

EFFICACY AND SAFETY OF EFGARTIGIMOD PH20 SUBCUTANEOUS IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: ADVANCE SC, A GLOBAL PHASE 3 CLINICAL TRIAL IN PROGRESS

Vickie McDonald - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Immune thrombocytopenia

Hyaluronidase

A CASE OF POLYCYTHAEMIA VERA TREATED WITH ROPEGINTERFERON-2B DURING PREGNANCY

I Sanchez - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Polycythaemia vera

Interferon

DEPTH OF RESPONSE AND MRD STATUS IN ULTRA HIGH-RISK MYELOMA AND PLASMA CELL LEUKEMIA TREATED WITH DARA-CVRD AND AUGMENTED AUTOLOGOUS TRANSPLANT: RESULTS OF THE RISK-STRATIFIED UK OPTIMUM/MUKNINE TRIAL

Martin Kaiser - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary plasma cell leukemia

Bortezomib

THE NATURAL HISTORY OF SYSTEMIC AL AMYLOIDOSIS FOLLOWING UPFRONT TREATMENT WITH BORTEZOMIB: AN ANALYSIS OF REAL-WORLD LONGITUDINAL DATA

Sriram Ravichandran - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

AL Amyloidosis

Bortezomib

LYMPHOCYTE COUNT EFFECT ON EFFICACY AND SAFETY OF SINGLE AGENT ORAL SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A POST-HOC ANALYSIS FROM PHASE 2B SADAL STUDY

Michael Schuster - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Selinexor

TARGETED LANDSCAPE REVIEW FOR UNDERSTANDING LYMPHOMA PATIENT-REPORTED OUTCOME ASSESSMENT IN THE ERA OF EMERGING THERAPIES

Stacie Hudgens - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non-Hodgkin's Lymphoma

Axicabtagene ciloleucel

THE SAFETY, PHARMACOKINETICS & PHARMACODYNAMIC EFFECTS OF IMR-687, A HIGHLY-SELECTIVE PDE9 INHIBITOR, IN ADULTS WITH SICKLE CELL DISEASE: PHASE-2A PLACEBO-CONTROLLED & OPEN-LABEL EXTENSION STUDIES

Biree Andemariam - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

Hydroxyurea

RAVULIZUMAB REDUCES THE RISK OF THROMBOSIS IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND HIGH DISEASE ACTIVITY: 2-YEAR DATA FROM A PHASE 3, OPEN-LABEL STUDY

Rgis Peffault de Latour - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

RELEASE OF INTERFERON-GAMMA BY AML CELLS REMODELS BONE MARROW IMMUNE MICROENVIRONMENT BY INDUCING REGULATORY T CELLS

Marilena Ciciarello - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Interferon Gamma

VALIDATION OF THE MYRADS REPORTING CRITERIA USING DATA FROM A PROSPECTIVE IMAGING STUDY IN PLASMA CELL DYSCRASIAS (LOOMIS).

Guido Nador - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

EUTOS EXPERIENCE OF STANDARDISATION OF MOLECULAR MONITORING FOR CML (2016 – 2020). USE OF SECONDARY BCR-ABL1 REFERENCE MATERIALS FOR CONVERSION FACTOR VALIDATION AND ASSESSMENT OF MR4.5 DETECTION

Helen White - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

L-Tyrosine

BASELINE CHARACTERISTICS BY AGE OF A GLOBAL COHORT OF PATIENTS DIAGNOSED WITH PYRUVATE KINASE DEFICIENCY – A DESCRIPTIVE ANALYSIS FROM THE PEAK REGISTRY

Paola Bianchi - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Pyruvate kinase (PK) deficiency

N/A

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN ELDERLY PATIENTS WITH RELAPSED MULTIPLE MYELOMA: IKEMA SUBGROUP ANALYSIS

Thierry Facon - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

ANALYSIS OF SURVIVAL IN PATIENTS WITH ACID SPHINGOMYELINASE DEFICIENCY TYPE B USING A LARGE, DEIDENTIFIED US ELECTRONIC HEALTH RECORD DATABASE

Amanda Wilson - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Niemann-Pick disease type A

N/A

CATEGORIZED HEMATOLOGIC RESPONSE TO PEGCETACOPLAN VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: POST HOC ANALYSIS OF PEGASUS PHASE 3 RANDOMIZED TRIAL DATA

Antonio Risitano - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

TRIAL IN PROGRESS: QUANTIFYING THE HUMANISTIC AND SOCIOECONOMIC BURDEN OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE COMMODORE BURDEN OF ILLNESS STUDY

Roger James Hampton - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

SEQUENTIAL NCRI AML TRIALS SHOW CONSISTENT BENEFIT FOR RIC TRANSPLANT IN CR1 FOR OLDER PATIENTS >60YEARS THAT IS INDEPENDENT OF MRD STATUS AFTER FIRST INDUCTION

Nigel Russell - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Daunorubicin

EXPERIENCES AND SUPPORT NEEDS OF CAREGIVERS OF PATIENTS WITH HIGHER-RISK MDS: QUALITATIVE INSIGHTS VIA ONLINE BULLETIN BOARD IN THE US, UK, AND CANADA

Pauline Frank MSc - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

REAL WORLD CLINICAL EFFECTIVENESS AND SAFETY OF CT-P10 IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY

Mark Bishton - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

CT-P10

USE OF CHIMERIC ANTIGEN RECEPTOR T CELL THERAPIES IN PATIENTS WITH LARGE B-CELL LYMPHOMA IN THE REAL-WORLD SETTING: SYSTEMATIC LITERATURE REVIEW

Fei Fei Liu - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

tisagenlecleucel-t

Filters

45280 Abstracts